← Back

Zhejiang Gongdong Medical Technology Co Ltd

Zhejiang Gongdong Medical Technology Co., Ltd. researches, develops, produces, and sells disposable medical consumables in China and internationally. Its products include blood collection tubes, needles, and needle holders, as well as sharps containers; cell culture dishes, plates, bottles, and flasks; serological pipettes; laboratory consumables such as petri dishes, centrifuge and cryo tubes, pipette tips, transfer pipettes, cuvettes, and test tubes; and urine, stool, and sputum specimen collection containers. The company also offers vaginal, ear, and anal specula, sponge forceps and nursing plasticwares, and customized plastic medical products. Founded in 1985, it is based in Taizhou, China.

Price · split & dividend adjusted
News & notes moving 605369.CG
605369.CG

Gongdong Medical Releases 2026 Interim Report with Net Profit of 54.6923 Million Yuan

Gongdong Medical released its 2026 interim report on August 25, 2026. The company's total operating revenue was 588 million yuan, net profit attributable to the parent was 54.6923 million yuan, and net cash inflow from operating activities was 130 million yuan. The company's latest asset-liability ratio was 20.65%, up 0.01 percentage points from the previous quarter and up 1.39 percentage points from the same period last year. The latest gross margin was 30.51%, down 1.95 percentage points from the previous quarter and down 0.80 percentage points from the same period last year. The latest return on equity was 3.22%, and diluted earnings per share was 0.25 yuan. The company's latest total asset turnover was 0.27 times, inventory turnover was 3.05 times, the number of shareholders was 10,700, and the top ten shareholders held 159 million shares, accounting for 71.89% of the total share capital.
605369.CG
Jiemian·25dRead more →
605369.CG▼

Gongdong Medical's first-half non-GAAP net profit attributable to parent was 53.07 million yuan, down 11.2% year-on-year

Gongdong Medical released its 2026 half-year report. First-half non-GAAP net profit attributable to the parent was 53.07 million yuan, down 11.2% year-on-year. Operating revenue was 588 million yuan, up 5.6% year-on-year. Net profit attributable to the parent was 54.69 million yuan, up 8.6% year-on-year. Net operating cash flow was 130 million yuan, up 45.2% year-on-year. Second-quarter operating revenue was 299 million yuan, up 2.4% year-on-year, and net profit attributable to the parent was 22.7 million yuan, down 1.0% year-on-year. The company's main business is the research, development, production and sales of disposable medical consumables. Management said business optimization implemented for the TPI segment led to a significant recovery in profitability.
605369.CG ▼
财中社·26dRead more →
605369.CG▲3

Gongdong Medical's wholly owned subsidiary receives US tariff refund of 940,700 dollars

Gongdong Medical's wholly owned subsidiary Trademark Plastics Inc. has recently received US tariff refunds totaling 940,700 dollars, including 901,000 dollars in tariffs and 39,700 dollars in interest. Based on the central parity rate of the RMB exchange rate on August 12, 2026, this is equivalent to approximately 6.39 million yuan, accounting for 12.40 percent of the company's most recently audited net profit attributable to shareholders of the listed company. In February 2026, the US Supreme Court ruled that the government lacked statutory authority to impose tariffs under the International Emergency Economic Powers Act, rendering the relevant tariff measures void from the outset, and tariffs already collected must be refunded to importers. US Customs and Border Protection officially began the refund process on April 20, 2026. The refunded amount is expected to be recognized in current-period profit or loss for 2026 and does not involve adjustments to prior-year profit or loss. The final accounting treatment and the amount of impact are subject to confirmation by the auditor.
605369.CG ▲
中国证券报·37dRead more →
© 2026 MarketDXAsset